Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.40B
Last updated: Nov 17, 2026 at 4:15 PM ET
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Statistics
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a market cap of $7.40B and an enterprise value of $10.42B. Its share count is up 6.86% from a year earlier. Its trailing P/E of 21.3x is above its 10-year median of 10.8x.
Total Valuation
Enterprise value is 40.84% above the market cap, as debt exceeds cash.
| Market Cap | $7.40B |
|---|---|
| Enterprise Value | $10.42B |
| Latest price (Nov 17, 2026) | $21.12 |
Key Dates
The next earnings report is expected on Feb 25, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 25, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.2x and 13.3x. Its year-end P/E ranged from 2.9x to 26.4x from 2016 to 2025.
| P/E Ratio | 21.3x |
|---|---|
| Forward P/E | 19.8x |
| P/S Ratio | 2.2x |
| Forward P/S | 2.3x |
| P/B Ratio | 13.3x |
| P/FCF Ratio | 184.5x |
| P/OCF Ratio | 41.0x |
| PEG Ratio | 0.9 |
Enterprise Valuation
Counting debt and cash, the company is valued at 15.2x EBITDA and 263.2x free cash flow.
| EV / Earnings | 49.7x |
|---|---|
| EV / Sales | 3.3x |
| EV / EBITDA | 15.2x |
| EV / EBIT | 22.9x |
| EV / FCF | 263.2x |
Price Statistics
The stock is up 81.44% over 52 weeks and trades 6.29% above its 50-day average.
| Beta (1Y) | 0.64 |
|---|---|
| 52-Week Change | +81.44% |
| 1-Month Change | +9.09% |
| 3-Month Change | +16.62% |
| 6-Month Change | +78.83% |
| 5-Year Change | +291.80% |
| 10-Year Change | +7.01% |
| Total Return (1Y) | +81.44% |
| Total Return (3Y CAGR) | +67.04% |
| Total Return (5Y CAGR) | +35.73% |
| Return vs SPY (1Y) | +70.98% |
| Max Drawdown (1Y) | -22.25% |
| Max Drawdown (3Y) | -24.65% |
| Sharpe Ratio (1Y) | 1.73 |
| Correlation with SPY (1Y) | 0.25 |
| 50-Day Average | $19.87 |
| 200-Day Average | $16.17 |
| 52-Week Range | $11.45 to $22.07 |
| RSI (14 Days) | 55.9 |
| Average Volume (20 Days) | 3.85M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.87x current liabilities, and total debt is 5.98x shareholder equity.
| Current Ratio | 1.87x |
|---|---|
| Quick Ratio | 1.24x |
| Debt / Equity | 5.98x |
| Debt / EBITDA | 4.79x |
| Debt / FCF | 82.72x |
| Interest Coverage | 13.12x |
Returns and Efficiency
Return on invested capital is 11.58% over the last 12 months, against a 5-year average of 6.43%.
| Return on Equity (ROE) | 39.43% |
|---|---|
| Return on Assets (ROA) | 3.98% |
| Return on Invested Capital (ROIC) | 11.58% |
| Return on Capital Employed (ROCE) | 10.95% |
| ROA (5Y Average) | -1.25% |
| ROIC (5Y Average) | 6.43% |
| Asset Turnover | 0.72x |
| Inventory Turnover | 2.76x |
| Receivables Turnover | 3.13x |
| Cash Conversion Cycle | 101 days |
Taxes
Income tax took 5.40% of pretax income over the last 12 months.
| Income Tax (TTM) | $11.96M |
|---|---|
| Effective Tax Rate | 5.40% |
Scores
AMRX has an Altman Z-Score of 1.92, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.92 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $3.20B over the last 12 months is up 8.88% from the 12 months before.
| Revenue | $3.20B |
|---|---|
| Revenue Growth (YoY) | +8.88% |
| Gross Profit | $1.29B |
| Operating Income | $478.99M |
| Pretax Income | $221.46M |
| Net Income | $209.49M |
| EBITDA | $663.62M |
| EBIT | $454.28M |
| Reported EPS (TTM) | $0.99 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 10.08% of the $5.27B in total assets.
| Cash and Equivalents | $157.40M |
|---|---|
| Total Debt | $3.18B |
| Net Debt | $3.02B |
| Net Debt Per Share | $9.00 |
| Working Capital | $975.18M |
| Shareholder Equity | $531.26M |
| Book Value Per Share | $1.58 |
| Tangible Book Value | -$1.79B |
| Total Assets | $5.27B |
| Total Liabilities | $4.63B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $142.20M of capital spending, operating cash flow left $38.42M of free cash flow.
| Operating Cash Flow | $180.63M |
|---|---|
| Capital Expenditures | $142.20M |
| Free Cash Flow | $38.42M |
| FCF Per Share | $0.11 |
| Depreciation and Amortization | $209.33M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 14.99%, against a 5-year average of 6.70%.
| Gross Margin | 40.24% |
|---|---|
| Operating Margin | 14.99% |
| Pretax Margin | 6.93% |
| Net Margin | 6.56% |
| EBITDA Margin | 20.77% |
| EBIT Margin | 14.22% |
| FCF Margin | 1.20% |
| Gross Margin (5Y Average) | 35.98% |
| Operating Margin (5Y Average) | 6.70% |
| Net Margin (5Y Average) | -2.20% |
Growth
Revenue grew 10.92% a year over 3 years, and EPS 7.30% a year.
| Revenue Growth (3Y CAGR) | +10.92% |
|---|---|
| Revenue Growth (5Y CAGR) | +8.66% |
| EPS Growth (3Y CAGR) | +7.30% |
| EPS Growth (5Y CAGR) | +5.92% |
| FCF Growth (3Y CAGR) | +145.46% |
| FCF Growth (5Y CAGR) | -5.33% |
Dividends and Yields
AMRX does not pay a dividend. Its free cash flow yield is 0.54%.
| Earnings Yield | 4.69% |
|---|---|
| FCF Yield | 0.54% |
| Shareholder Yield | 0.00% |
Peer Position
Against 11 similar companies, AMRX has the 6th highest P/E.
P/E RatioPeer median 18.5x
P/S RatioPeer median 3.0x
ROICPeer median 7.85%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +20.61%
| P/E Ratio | 21.3x vs 18.5x median |
|---|---|
| P/S Ratio | 2.2x vs 3.0x median |
| ROIC | 11.58% vs 7.85% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +8.88% vs +20.61% median |
Analyst Forecast
Consensus estimates put revenue growth at 7.78% and EPS growth at 21.15% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +7.78% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +21.15% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About AMRX
What is AMRX's market cap?
Amneal Pharmaceuticals, Inc. Class A Common Stock has a market cap of $7.40B. Its enterprise value, which adds debt and subtracts cash, is $10.42B.
What is AMRX's P/E ratio?
Amneal Pharmaceuticals, Inc. Class A Common Stock has a trailing P/E ratio of 21.3x and a forward P/E of 19.8x.
How many shares of AMRX are outstanding?
Amneal Pharmaceuticals, Inc. Class A Common Stock has 335.73M shares outstanding. The count is up 6.86% from a year earlier.
Does AMRX pay a dividend?
No. Amneal Pharmaceuticals, Inc. Class A Common Stock does not pay a dividend.
How much debt does AMRX have?
Amneal Pharmaceuticals, Inc. Class A Common Stock has $3.18B of total debt and $157.40M of cash and equivalents, a net debt position of $3.02B.
AMRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors